Analytical performance of an automated immunoassay for tissue inhibitor of me talloproteinases-1 (TIMP-1)

Gerard J. Davis, Philip M. Hemken, Willard Dunn, Sabrina S. Chan, Renu Dua, Lori J Sokoll, Barry L. Dowell, Thomas T. Biegalski, Debra Elliott, Daniel Wan-Yui Chan

Research output: Contribution to journalArticle

Abstract

Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) measurements may be clinically useful in colorectal cancer detection and management, cardiac disease risk assessment, and in liver fibrosis monitoring. The analytical performance for an automated ARCHITECT® TIMP-1 immunoassay was evaluated, including precision, on-board reagent stability, effect of interfering substances, specimen collection and handling, analytical sensitivity, linearity, recovery, manual vs. autodilution, high-dose hook effect, and reagent lot-to-lot agreement. Precision was evaluated over 20 days across 2 test sites, 3 instruments, and 3 reagent lots. Total concentration CVs for a plasma panel and for low, medium, and high controls were 2.3, 2.8, 3.2, and 5.3%, respectively. No interferences were observed for other TIMPs, common interferences, and chemotherapeutic compounds. TIMP-1 results in plasma from EDTA, heparin, and plasma separator tubes showed no significant difference (

Original languageEnglish (US)
Pages (from-to)70-76
Number of pages7
JournalJournal of Clinical Ligand Assay
Volume30
Issue number3-4
StatePublished - Sep 2007

Fingerprint

Immunoassay
Specimen Handling
Tissue
Plasmas
Tissue Inhibitor of Metalloproteinase-1
Hooks
Separators
Edetic Acid
Liver Cirrhosis
Liver
Risk assessment
Heparin
Colorectal Neoplasms
Heart Diseases
Recovery
Monitoring

Keywords

  • Biomarker
  • Colorectal cancer
  • Immunoassay development
  • TIMP-1

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Analytical performance of an automated immunoassay for tissue inhibitor of me talloproteinases-1 (TIMP-1). / Davis, Gerard J.; Hemken, Philip M.; Dunn, Willard; Chan, Sabrina S.; Dua, Renu; Sokoll, Lori J; Dowell, Barry L.; Biegalski, Thomas T.; Elliott, Debra; Chan, Daniel Wan-Yui.

In: Journal of Clinical Ligand Assay, Vol. 30, No. 3-4, 09.2007, p. 70-76.

Research output: Contribution to journalArticle

Davis, GJ, Hemken, PM, Dunn, W, Chan, SS, Dua, R, Sokoll, LJ, Dowell, BL, Biegalski, TT, Elliott, D & Chan, DW-Y 2007, 'Analytical performance of an automated immunoassay for tissue inhibitor of me talloproteinases-1 (TIMP-1)', Journal of Clinical Ligand Assay, vol. 30, no. 3-4, pp. 70-76.
Davis, Gerard J. ; Hemken, Philip M. ; Dunn, Willard ; Chan, Sabrina S. ; Dua, Renu ; Sokoll, Lori J ; Dowell, Barry L. ; Biegalski, Thomas T. ; Elliott, Debra ; Chan, Daniel Wan-Yui. / Analytical performance of an automated immunoassay for tissue inhibitor of me talloproteinases-1 (TIMP-1). In: Journal of Clinical Ligand Assay. 2007 ; Vol. 30, No. 3-4. pp. 70-76.
@article{d788ea318c5041cea73b4f1816bcf7f9,
title = "Analytical performance of an automated immunoassay for tissue inhibitor of me talloproteinases-1 (TIMP-1)",
abstract = "Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) measurements may be clinically useful in colorectal cancer detection and management, cardiac disease risk assessment, and in liver fibrosis monitoring. The analytical performance for an automated ARCHITECT{\circledR} TIMP-1 immunoassay was evaluated, including precision, on-board reagent stability, effect of interfering substances, specimen collection and handling, analytical sensitivity, linearity, recovery, manual vs. autodilution, high-dose hook effect, and reagent lot-to-lot agreement. Precision was evaluated over 20 days across 2 test sites, 3 instruments, and 3 reagent lots. Total concentration CVs for a plasma panel and for low, medium, and high controls were 2.3, 2.8, 3.2, and 5.3{\%}, respectively. No interferences were observed for other TIMPs, common interferences, and chemotherapeutic compounds. TIMP-1 results in plasma from EDTA, heparin, and plasma separator tubes showed no significant difference (",
keywords = "Biomarker, Colorectal cancer, Immunoassay development, TIMP-1",
author = "Davis, {Gerard J.} and Hemken, {Philip M.} and Willard Dunn and Chan, {Sabrina S.} and Renu Dua and Sokoll, {Lori J} and Dowell, {Barry L.} and Biegalski, {Thomas T.} and Debra Elliott and Chan, {Daniel Wan-Yui}",
year = "2007",
month = "9",
language = "English (US)",
volume = "30",
pages = "70--76",
journal = "Journal of Clinical Ligand Assay",
issn = "1081-1672",
publisher = "Clinical Ligand Assay Society Inc.",
number = "3-4",

}

TY - JOUR

T1 - Analytical performance of an automated immunoassay for tissue inhibitor of me talloproteinases-1 (TIMP-1)

AU - Davis, Gerard J.

AU - Hemken, Philip M.

AU - Dunn, Willard

AU - Chan, Sabrina S.

AU - Dua, Renu

AU - Sokoll, Lori J

AU - Dowell, Barry L.

AU - Biegalski, Thomas T.

AU - Elliott, Debra

AU - Chan, Daniel Wan-Yui

PY - 2007/9

Y1 - 2007/9

N2 - Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) measurements may be clinically useful in colorectal cancer detection and management, cardiac disease risk assessment, and in liver fibrosis monitoring. The analytical performance for an automated ARCHITECT® TIMP-1 immunoassay was evaluated, including precision, on-board reagent stability, effect of interfering substances, specimen collection and handling, analytical sensitivity, linearity, recovery, manual vs. autodilution, high-dose hook effect, and reagent lot-to-lot agreement. Precision was evaluated over 20 days across 2 test sites, 3 instruments, and 3 reagent lots. Total concentration CVs for a plasma panel and for low, medium, and high controls were 2.3, 2.8, 3.2, and 5.3%, respectively. No interferences were observed for other TIMPs, common interferences, and chemotherapeutic compounds. TIMP-1 results in plasma from EDTA, heparin, and plasma separator tubes showed no significant difference (

AB - Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) measurements may be clinically useful in colorectal cancer detection and management, cardiac disease risk assessment, and in liver fibrosis monitoring. The analytical performance for an automated ARCHITECT® TIMP-1 immunoassay was evaluated, including precision, on-board reagent stability, effect of interfering substances, specimen collection and handling, analytical sensitivity, linearity, recovery, manual vs. autodilution, high-dose hook effect, and reagent lot-to-lot agreement. Precision was evaluated over 20 days across 2 test sites, 3 instruments, and 3 reagent lots. Total concentration CVs for a plasma panel and for low, medium, and high controls were 2.3, 2.8, 3.2, and 5.3%, respectively. No interferences were observed for other TIMPs, common interferences, and chemotherapeutic compounds. TIMP-1 results in plasma from EDTA, heparin, and plasma separator tubes showed no significant difference (

KW - Biomarker

KW - Colorectal cancer

KW - Immunoassay development

KW - TIMP-1

UR - http://www.scopus.com/inward/record.url?scp=63449123486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63449123486&partnerID=8YFLogxK

M3 - Article

VL - 30

SP - 70

EP - 76

JO - Journal of Clinical Ligand Assay

JF - Journal of Clinical Ligand Assay

SN - 1081-1672

IS - 3-4

ER -